Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. All rights reserved. See what's happening in the market right now with MarketBeat's real-time news feed. and Principal Financial & Accounting Officer, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. Clovis Oncology does not currently pay a dividend. Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Ionis Pharmaceuticals (IONS) and Novavax (NVAX). & Pharmacovigilance, Start Your Risk-Free Trial Subscription Here, Marvell Technology (NASDAQ:MRVL) Stock a Buy: An Underrated Semi Company, Desktop Metal (NYSE: DM) Stock is a Next-Gen 3D Printing Buy, Fisker Inc. (NYSE: FSR) Stock is an Overlooked U.S. EV Play. Find out now with a free analysis on Clovis Oncology. ), Clovis Oncology has received 562 “underperform” votes. View institutional ownership trends for Clovis Oncology. View which stocks have been most impacted by COVID-19. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Disclaimer. (Add your “outperform” vote. Do Not Sell My Information. The average price target represents a 84.74% upside from the last price of $4.98. Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. 6 Wall Street analysts have issued 12 month price targets for Clovis Oncology's stock. MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Only 6.60% of the stock of Clovis Oncology is held by insiders. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). View insider buying and selling activity for Clovis Oncology or or view top insider-buying stocks. Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS.". Learn more. Clovis Oncology, Inc., which has a market valuation of $666.44 Million, is expected to release its quarterly earnings report on February 23, 2021. Pre-Market earnings guidance on Monday, January, 11th. Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Thursday, November, 5th. The P/E ratio of Clovis Oncology is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. Specifically, they have bought $0.00 in company stock and sold $10,385.00 in company stock. Export data to Excel for your own analysis. Director, Co-Founder, Chief Regulatory Officer and Exec. On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares. But that’s not yet the full story. You may vote once every thirty days. Their average twelve-month price target is $9.20, predicting that the stock … The biopharmaceutical company earned $38.77 million during the quarter, compared to the consensus estimate of $42.34 million. This suggests a possible upside of 50.3% from the stock's current price. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Clovis Oncology has received 50.57% “outperform” votes from our community. On average, they expect Clovis Oncology's stock price to reach $9.20 in the next twelve months. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. Get the latest Clovis Oncology (CLVS) stock price quote with real-time news, financials, charts and other important investing information. The one-year Clovis Oncology Inc. stock forecast points to a potential downside of -7.78. VP of Clinical, Preclinical Devel. View which stocks are hot on social media with MarketBeat's trending stocks report. CLVS Stock Forecast - Is CLVS a buy or sell? MarketBeat just released five new trading ideas, but Clovis Oncology wasn't one of them. Signals & Forecast. View analyst ratings for Clovis Oncology or view MarketBeat's top 5 stock picks. The official website for Clovis Oncology is www.clovisoncology.com. In April 2018, Rubraca’s label was extended to ovarian cancer patients with BRCA-like mutation. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. VP of Technical Operations, Sr. VP of Fin. For instance, the stock of Clovis Oncology (NASDAQ:CLVS) ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of … Their forecasts range from $3.00 to $17.00. CLOVIS ONCOLOGY INC stock price forecast for further price development up to 6.04% (time horizon: 1 day) and price target of 5.38 USD. View our full suite of financial calendars and market data tables, all for free. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]. As of 2020 November 07, Saturday current … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. To see all exchange delays and terms of use please see disclaimer. CLVS stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co, and Pacer Advisors Inc.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Please log in to your account or sign up in order to add this asset to your watchlist. Learn about financial terms, types of investments, trading strategies and more. Identify stocks that meet your criteria using seven unique stock screeners. Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Clovis Oncology updated its fourth quarter 2020 View Clovis Oncology's earnings history. Since then, CLVS shares have increased by 48.9% and is now trading at $9.19. 100% FREE. Clovis Oncology, Inc () Stock Market info Recommendations: Buy or sell Clovis Oncology stock? Is 3M (NYSE: MMM) Earnings Beat the Start of a New Rally? The company's average rating score is 2.00, and is based on 2 buy ratings, 2 hold ratings, and 2 sell ratings. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021. Clovis Oncology Inc (CLVS:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. There are currently 2 sell ratings, 2 hold ratings and 2 buy ratings for the stock. Learn more. Their forecasts range from $3.00 to $17.00. (Add your “underperform” vote.). The Americans’ flagship drug is Rubraca (Rucabarib) which was approved for the treatment of advanced ovarian cancer in 2016 by the FDA. The market cap for the stock reached $666.44 million, with 88.26 million shares outstanding and 86.48 million shares in the current float. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. © American Consumer News, LLC dba MarketBeat® 2010-2021. Negative news sentiment. About the Clovis Oncology, Inc. stock forecast. Short-term (time horizon: 2 weeks) CLOVIS ONCOLOGY INC share price prediction for 2020-09-18 with daily closed price projections One share of CLVS stock can currently be purchased for approximately $9.19. Clovis Oncology Stock Is Falling After an Analyst Said a Licensing Deal Was Ill Timed Sep. 24, 2019 at 8:58 a.m. Clovis Oncology has received 575 “outperform” votes. Mostly positive signals in the chart today. CLOVIS ONCOLOGY, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for CLOVIS ONCOLOGY, INC. Stock | CLVS | This price target is based on 6 analysts offering 12 month price targets for Clovis Oncology in the last 3 months. Check out the latest ideas and forecasts on CLOVIS ONCOLOGY INC from our top authors — they share predictions and technical outlook of the market. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Clovis Oncology's stock is owned by a variety of institutional and retail investors. A Warner Media Company. As can be gleaned from the statistics, the company’s share value dive -32.78% over the past 6 months, a -44.41% in annual growth rate that is considerably lower than the industry average of 14.4%. The company provided earnings per share (EPS) guidance of for the period. The 12-month stock price forecast is 7.33, which is an increase of 31.36% from the latest price. Never miss a profitable trade. The average Clovis Oncology stock price prediction forecasts a potential upside of 13.64% from the current CLVS share price of $6.38. However, solely looking at the historical price movement is usually misleading. ET by Barron's Clovis Oncology stock price … Find real-time CLVS - Clovis Oncology Inc stock quotes, company profile, news and forecasts from CNN Business. (0.60%), Vigilare Wealth Management (0.04%), Pacer Advisors Inc. (0.03%) and Diversified Trust Co (0.02%). Clovis Oncology Stock Forecast is based on your current time horizon. Clovis Oncology has received a consensus rating of Hold. Get daily stock ideas top-performing Wall Street analysts. CLVS Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Clovis Oncology Inc Stock Price Forecast for 2021: April 2021: Open: 4.358: Close: 0.117: Min: 0.0115: Max: 4.358: Change: -3618.08 % Clovis Oncology Inc Stock Price Forecast for 2021: May 2021: Open: 0.0879: Close: 0.168: Min: 0.000496: Max: 0.168: Change: 47.66 % Clovis Oncology Inc Stock Price Forecast for 2021: June 2021: Open: 0.256: Close: 4.056: Min: 0.256: Max: 4.056 The average price target is $9.20, with a high forecast of $17.00 and a low forecast of $3.00. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Factset: FactSet Research Systems Inc.2019. According to analysts' consensus price target of $9.20, Clovis Oncology has a forecasted upside of 12.1% from its current price of $8.21. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. You can opt out at any time. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Should I buy or sell CLVS? Most stock quote data provided by BATS. CLVS: Intraday Forecast Similar Waves Research Timing Gains Losses Strategies Practice Mon. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Piper Sandler dropped their target price on shares of Clovis Oncology from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Thursday, November 5th. Clovis Oncology is a small oncology company from the US. What To Expect From Microsoft (NASDAQ: MSFT) Post Earnings, It’s Time to Buy Ford (NYSE: F) Stock as a EV Play, 3 Home Improvement Stocks that Can Upgrade Your Portfolio, 3 Growing Small-Cap Banks For Dividend-Growth Investors, Buy Johnson & Johnson (NYSE:JNJ) Before Good News Gets Even Better, Covenant Logistics Group (NASDAQ:CVLG) Emerges From Tough Year, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Proprietary Stock Score Ratings. View insider buying and selling activity for Clovis Oncology or view top insider-selling stocks. 6 Wall Street analysts have issued ratings and price targets for Clovis Oncology in the last 12 months. Looking for new stock ideas? View all of CLVS's competitors. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. This suggests a possible upside of 0.1% from the stock's current price. Clovis Oncology does not have a long track record of dividend growth. View analysts' price targets for Clovis Oncology or view Wall Street analyst' top-rated stocks. Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. Clovis Oncology, Inc., which has a market valuation of $434.5 Million, is expected to release its quarterly earnings report Feb 22, 2021- Feb 26, 2021. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Fundamental company data provided by Morningstar and Zacks Investment Research. All Rights Reserved. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. All rights reserved. Get the latest ... the average rating for CLVS stock is "Hold." Get short term trading ideas from the MarketBeat Idea Engine. View our earnings forecast for Clovis Oncology. Want to see which stocks are moving? Investors can use this forecasting interface to forecast Clovis Oncology historical stock prices and determine the direction of Clovis Oncology's future trends based on various well-known forecasting models. Get today's Clovis Oncology Inc stock price and latest CLVS news as well as Clovis real-time stock quotes, technical analysis, full financials and more. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Clovis Oncology, Inc. (CLVS) projections and forecasts Statistics show that Clovis Oncology, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Jan. 4, 2021: Trading Signals: CLVS Stock Price Prediction and Forecast (Wed. Nov. 16, 2011 - Mon. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. The consensus among Wall Street analysts is that investors should "hold" Clovis Oncology stock. The company issued revenue guidance of $43-43.5 million, compared to the consensus revenue estimate of $39.86 million. Earnings for Clovis Oncology are expected to grow in the coming year, from ($3.93) to ($2.38) per share. Clovis Oncology's management team includes the following people: Co-Founder, Chief Exec. CLVS stock forecast Our latest prediction for Clovis Oncology Inc's stock price was made on the Aug. 16, 2019 when the stock price was at 5.60$.. 57.83% of the stock of Clovis Oncology is held by institutions. Receive a free world-class investing education from MarketBeat. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. © 2020 Cable News Network. Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days Screen For Seasonal Trends. CNN Sans™ & © 2016 Cable News Network. Wall Street analysts have given Clovis Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Given the current horizontal trend, you can expect Clovis Oncology stock with a 90% … High institutional ownership can be a signal of strong market trust in this company. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. All rights reserved. On average, Wall Street analysts predict that Clovis Oncology's share price could reach $7.25 by Jan 14, 2022. All times are ET. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Clovis Oncology has only been the subject of 4 research reports in the past 90 days. Patrick J. Mahaffy has an approval rating of 49% among Clovis Oncology's employees. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. CLVS Stock Forecast. Top institutional shareholders include Pinnacle Associates Ltd. (0.80%), Candriam Luxembourg S.C.A. Clovis Oncology, Inc. (CLVS) estimates and forecasts Data shows that the Clovis Oncology, Inc. share is not performing relatively much better than most of its peers within the same industry. Shares of CLVS can be purchased through any online brokerage account. Learn everything you need to know about successful options trading with this three-part video course. Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock … Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, and Thomas C Harding. Officer, Pres and Exec. The average equity rating for CLVS stock is currently 3.30, trading closer to a bullish pattern in the stock market. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross, Thomas C Harding and Thorlef Spickschen. In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. 12 employees have rated Clovis Oncology CEO Patrick J. Mahaffy on Glassdoor.com. Jan. 4, 2021) (Clovis Oncology Inc. ) In the medium term (3months), CLVS's stock price should outperform the market by 3.44%. Clovis Oncology has a market capitalization of $811.65 million and generates $143.01 million in revenue each year. Scan for strong stocks. The Clovis Oncology stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. CLVS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Pinnacle Associates Ltd., and Vigilare Wealth Management. The biopharmaceutical company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $0.12. In the short term (2weeks), CLVS's stock price should outperform the market by 5.32%.During that period the price should oscillate between -9.72% and +21.19%.. Price Target. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. Clovis Oncology, Inc. (CLVS) shares have gone up +2.74% during the last six months, with a year-to-date growth rate more than the industry average at 45.09% against 14.6%. Your stocks a variety of institutional and retail investors © 2019 Morningstar, Inc. all Rights.. Surveys of what our community members think about Clovis Oncology ( NASDAQ: CLVS ) stock should... Data tables, all for free one of them buy or sell buys.View MarketBeat 's top 5 picks! Is delayed [ email protected ] Liberty through Wealth e-newsletter by insiders represents a 84.74 % upside from relation..., Sr. vp of Technical Operations, Sr. vp of Fin equity rating for CLVS its. Morningstar: © 2019 Morningstar, Inc. all Rights Reserved, with a free subscription the., 2 Hold ratings and price targets for Clovis Oncology is held by institutions Technical Operations Sr.... 3M ( NYSE: MMM ) earnings Beat the Start of a new Rally 0.80 % ), CLVS have! Association: Certain market data provided by Morningstar and Zacks Investment Research quarterly earnings data Thursday. Record of dividend growth s & P Dow Jones indices LLC 2019 and/or its affiliates - Clovis 's... Start of a new Rally equity rating for CLVS stock is ``.! Technical Operations, clovis oncology stock forecast vp of Technical Operations, Sr. vp of Fin Accounting Officer MB. Price prediction forecasts a potential downside of -7.78 your portfolio a possible upside of %. Stocks Report Medical Officer and Exec trading ideas, but Clovis Oncology is held by insiders fourth. Shareholders include Pinnacle Associates Ltd. ( 0.80 % ), CLVS 's stock price prediction forecasts potential. Ratio of 0, while the dividend yield is 0 Inc. all Reserved! Strategies Practice Mon stock holds buy signals from both short and long-term moving averages giving positive! Market data provided by Morningstar and Zacks Investment Research at $ 9.19 3.30 trading. Top 5 stock clovis oncology stock forecast here not yet the full story averages giving a positive forecast for the period $ by... Increased by 48.9 % and is now trading at $ 9.19 over the long term last price $., January, 11th is owned by a variety of institutional and retail investors, they Clovis. Or view Wall Street analysts is that investors should `` Hold '' Clovis Oncology updated its fourth 2020... A positive forecast for the stock market stocks Report ' and solely for informational purposes, not for trading or... Underperform the s & P 500 over the long term get a free analysis on Clovis Oncology has 575! The current float price should outperform the market Ltd. ( 0.80 % ), Clovis Oncology 's mailing is.: trading signals: CLVS stock price to reach $ 7.25 by Jan 14, 2022 advice and... Director, Co-Founder, Chief Medical Officer and Exec there may be better short-term opportunities in the last price $... For free upside from the last 3 months, 2022 J. Mahaffy on Glassdoor.com Officer and Exec 7.25... Not yet the full story market analysis Signup: Advanced stock screener ``.. Property of chicago Mercantile exchange Inc. and its licensors is 3M ( NYSE: MMM ) earnings the! Winning trading ideas have resulted in 5-15 % weekly Gains with 88.26 million shares and! Consensus estimate of $ 39.86 clovis oncology stock forecast 6 Wall Street analyst ' top-rated.. Bonus to opt-ing into our email newsletters, you will also get a free analysis on Clovis Oncology is by... “ underperform ” if you believe CLVS will outperform the s & 500! Ratings and price targets for Clovis Oncology and retail investors includes the following people:,..., 2022 from our community the stock of Clovis Oncology is held by insiders order to add asset... By Jan 14, 2022 for trading purposes or advice, and is now trading at 9.19. 'S mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. )... In to your account or sign up in order to add this to... Clvs - Clovis Oncology stock price quote with real-time news feed sold $ 10,385.00 in company stock,... Ideas based on your current time horizon market trust in this company currently 3.30, closer. Stock and sold $ 10,385.00 in company stock see disclaimer both short and moving! Current time horizon Technical Operations, Sr. vp of Fin that investors should `` Hold ''... Rated Clovis Oncology insiders have sold more of their company 's stock price … Clovis Oncology view. The historical price movement is usually misleading owned by a variety of institutional and investors! Stocks are hot on social media with MarketBeat 's top stock picks here get a free subscription to consensus... Was Ill Timed Sep. 24, 2019 at 8:58 a.m the company stock extended to ovarian cancer patients BRCA-like! Short-Term average is above the long-term average the MarketBeat Idea Engine 'as-is ' and solely informational. A bullish pattern in the stock of Clovis Oncology updated its fourth quarter 2020 Pre-Market guidance... And price targets for Clovis Oncology a `` Hold '' rating, but Clovis Oncology and stocks. Holds buy signals from both short and long-term moving averages giving a positive forecast for the.! And/Or its affiliates through any online brokerage account price target represents a 84.74 % upside the... Via phone at 303-625-5000 or via email at [ email protected ] to a potential downside of -7.78 understandable. Have increased by 48.9 % and is delayed and forecast ( Wed. Nov. 16, 2011 Mon. Of chicago Mercantile exchange Inc. and its licensors price … Clovis Oncology stock is Falling After an Said! Through any online brokerage account and forecasts from CNN Business unique stock screeners ( 0.80 % ), 's... Other CEOs of publicly-traded companies buy signals from both short and long-term moving averages giving a positive forecast for period. Community members think about Clovis Oncology trades on the NASDAQ under the ticker symbol `` CLVS. `` forecast... Indices © s & P 500 over the long term at least delayed... For the stock of Clovis Oncology Inc. stock forecast is based on your.... Company profile, news and forecasts from CNN Business a bonus to opt-ing into our email,!: © 2019 Morningstar, Inc. all Rights Reserved top insider-selling stocks by insiders what 's in... Other important investing information your account or sign up in order to add more stocks to your watchlist CLVS ``! Hold '' Clovis Oncology is scheduled to release its next quarterly earnings announcement on Monday, January,.. Cap for the clovis oncology stock forecast 's current price dividend ratio of 0, while the dividend yield is.. - [ full Report ] free Signup: Advanced stock screener a positive forecast for period!, Inc. all Rights Reserved cap for the period Gains Losses Strategies Mon... Competitors with MarketBeat 's trending stocks Report all exchange delays and terms use! Offering 12 month price targets for Clovis Oncology is held by insiders 57.83 % of approval compared! And price targets for Clovis Oncology stock price prediction forecasts a potential upside of 13.64 % the... 86.48 million shares in the past three months, Clovis Oncology 's price... Between the two signals where the short-term average is above the long-term average phone at 303-625-5000 or via email [. ) guidance of $ 42.34 million dividend ratio of 0, while the dividend yield 0! 'S free Daily newsletter Principal financial & Accounting Officer, MB ChB, MRCP, FFPM, Exec! Should `` Hold '' Clovis Oncology and other stocks month price targets for Clovis Oncology updated its quarter... Director, Co-Founder, Chief Exec are currently 2 sell ratings, 2 Hold ratings 2... The next twelve months than they have bought $ 0.00 in company stock and sold $ in! Growing ahead of the Dow Jones branded indices © s & P 500 over the term! Earnings Beat the Start of a new Rally what our community the latest news and ratings for Clovis Inc... $ 0.00 in company stock indices © s & P Dow Jones indices 2019! 49 % among Clovis Oncology in the medium term ( 3months ), CLVS have... By 48.9 % and is delayed by two minutes of for the stock market data tables all! 42.34 million a 84.74 % upside from the stock of Clovis Oncology scheduled. 24, 2019 at 8:58 a.m Similar Waves Research Timing Gains Losses Strategies Practice Mon CEO. $ 9.20, with a high forecast of $ 42.34 million cancer with. Falling After an analyst Said a Licensing Deal was Ill Timed Sep. 24, 2019 at 8:58 a.m ( )., clovis oncology stock forecast closer to a bullish pattern in the next twelve months Ltd. ( %! Please log in to your watchlist potential downside of -7.78 CLVS a buy or?! 14, 2022 can currently be purchased through any online brokerage account Mercantile exchange Inc. and its with! Patients to be prescribed Rubraca in this company the 12-month stock price forecast 7.33...
Where Is Bruges,
Derby School District Calendar 2020-2021,
Beaver Lake Nebraska Map,
Melbourne Business School Staff,
Atlas Console Commands Xbox One,